LITE vs. BBIO
LITE (Lumentum Holdings Inc.) and BBIO (BridgeBio Pharma, Inc.) are both stocks. LITE operates in Communication Equipment (Technology), while BBIO operates in Biotechnology (Healthcare). Over the past 5 years, LITE returned 62.02%/yr vs 1.89%/yr for BBIO. At a 0.26 correlation, their price movements are largely independent.
Performance
LITE vs. BBIO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, LITE achieves a 142.93% return, which is significantly higher than BBIO's -11.92% return.
LITE
- 1D
- 3.68%
- 1M
- -0.93%
- YTD
- 142.93%
- 6M
- 161.38%
- 1Y
- 999.19%
- 3Y*
- 159.80%
- 5Y*
- 62.02%
- 10Y*
- 43.30%
BBIO
- 1D
- -0.35%
- 1M
- -0.03%
- YTD
- -11.92%
- 6M
- -9.25%
- 1Y
- 74.44%
- 3Y*
- 61.48%
- 5Y*
- 1.89%
- 10Y*
- —
LITE vs. BBIO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
LITE Lumentum Holdings Inc. | 142.93% | 339.06% | 60.15% | 0.48% | -50.68% | 11.57% | 19.55% | 51.25% |
BBIO BridgeBio Pharma, Inc. | -11.92% | 178.75% | -32.03% | 429.79% | -54.32% | -76.54% | 102.88% | 27.22% |
Correlation
The correlation between LITE and BBIO is 0.17, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.17 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.25 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.27 |
Correlation (All Time) Calculated using the full available price history since Jun 28, 2019 | 0.26 |
Fundamentals
LITE:
$86.14B
BBIO:
$13.12B
LITE:
$5.26
BBIO:
-$3.76
LITE:
30.07
BBIO:
23.00
LITE:
$2.49B
BBIO:
$566.04M
LITE:
$938.50M
BBIO:
$538.20M
LITE:
$470.10M
BBIO:
-$602.24M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
LITE vs. BBIO — Risk / Return Rank
LITE
BBIO
LITE vs. BBIO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Lumentum Holdings Inc. (LITE) and BridgeBio Pharma, Inc. (BBIO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| LITE | BBIO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +10.16 | ||
| Sortino ratioReturn per unit of downside risk | +3.26 | ||
| Omega ratioGain probability vs. loss probability | 1.73 | 1.30 | +0.43 |
| Calmar ratioReturn relative to maximum drawdown | 35.18 | 3.70 | +31.48 |
| Martin ratioReturn relative to average drawdown | 134.51 | 9.25 | +125.26 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| LITE | BBIO | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 11.76 | 1.60 | +10.16 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 1.04 | 0.02 | +1.02 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.77 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.75 | 0.16 | +0.58 |
Drawdowns
LITE vs. BBIO - Drawdown Comparison
The maximum LITE drawdown since its inception was -66.89%, smaller than the maximum BBIO drawdown of -92.80%. Use the drawdown chart below to compare losses from any high point for LITE and BBIO.
Loading charts...
Drawdown Indicators
| LITE | BBIO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -66.89% | -92.80% | +25.91% |
Max Drawdown (1Y)Largest decline over 1 year | -28.70% | -20.25% | -8.45% |
Max Drawdown (3Y)Largest decline over 3 years | -50.63% | -49.08% | -1.55% |
Max Drawdown (5Y)Largest decline over 5 years | -66.48% | -91.89% | +25.41% |
Max Drawdown (10Y)Largest decline over 10 years | -66.89% | — | — |
Current DrawdownCurrent decline from peak | -14.97% | -15.69% | +0.72% |
Average DrawdownAverage peak-to-trough decline | -23.16% | -45.80% | +22.64% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.49% | 8.07% | -0.58% |
Volatility
LITE vs. BBIO - Volatility Comparison
Lumentum Holdings Inc. (LITE) has a higher volatility of 31.18% compared to BridgeBio Pharma, Inc. (BBIO) at 12.10%. This indicates that LITE's price experiences larger fluctuations and is considered to be riskier than BBIO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| LITE | BBIO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 31.18% | 12.10% | +19.08% |
Volatility (6M)Calculated over the trailing 6-month period | 69.07% | 34.41% | +34.66% |
Volatility (1Y)Calculated over the trailing 1-year period | 86.01% | 46.75% | +39.26% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 59.79% | 85.95% | -26.16% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 56.55% | 83.80% | -27.25% |
Dividends
LITE vs. BBIO - Dividend Comparison
Neither LITE nor BBIO has paid dividends to shareholders.
Financials
LITE vs. BBIO - Financials Comparison
This section allows you to compare key financial metrics between Lumentum Holdings Inc. and BridgeBio Pharma, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
LITE vs. BBIO - Profitability Comparison
LITE - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Lumentum Holdings Inc. reported a gross profit of 357.00M and revenue of 808.40M. Therefore, the gross margin over that period was 44.2%.
BBIO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported a gross profit of 178.39M and revenue of 180.60M. Therefore, the gross margin over that period was 98.8%.
LITE - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Lumentum Holdings Inc. reported an operating income of 174.50M and revenue of 808.40M, resulting in an operating margin of 21.6%.
BBIO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported an operating income of -105.96M and revenue of 180.60M, resulting in an operating margin of -58.7%.
LITE - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Lumentum Holdings Inc. reported a net income of 144.20M and revenue of 808.40M, resulting in a net margin of 17.8%.
BBIO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported a net income of -164.04M and revenue of 180.60M, resulting in a net margin of -90.8%.
Frequently Asked Questions
LITE and BBIO have a correlation of 0.17, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
LITE has higher volatility (31.18%) compared to BBIO (12.10%). In terms of maximum drawdown, LITE dropped -66.89% vs BBIO's -92.80%.
LITE currently has the higher Sharpe Ratio (11.76 vs 1.60), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for LITE and BBIO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer